98455-00-6

Basic information

• Product Name: 1-Piperazinepropanethiol,4-methyl-(9CI)
• Synonyms: 1-Piperazinepropanethiol,4-methyl-(9CI);3-(4-METHYLPIPERAZIN-1-YL)PROPANE-1-THIOL
• CAS NO: 98455-00-6
• Molecular Formula: C8 H18 N2 S
• Molecular Weight: 0
• Product Categories: PIPERIDINE
• Mol File: 98455-00-6.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-Piperazinepropanethiol,4-methyl-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Piperazinepropanethiol,4-methyl-(9CI)(98455-00-6)
• EPA Substance Registry System: 1-Piperazinepropanethiol,4-methyl-(9CI)(98455-00-6)

Safety Data

• Hazardous Substances Data: 98455-00-6(Hazardous Substances Data)

Usage

Uses

Precursors in the synthesis of pharmaceuticals and agrochemicals, corrosion inhibitor, reagent in organic synthesis

Physical properties

Colorless to pale yellow liquid, characteristic odor, soluble in water, alcohols, and ether

Toxicity

Moderately toxic, irritant to skin, eyes, and respiratory system

Safety measures

Proper safety measures should be taken when handling this chemical.

Upstream product

• 109-01-3 1-methyl-piperazine 
• 104-16-5 3-(N-methylpiperazinyl)propyl chloride 
• 507-09-5 tiolacetic acid 

Relevant articles and documents

Design, synthesis and biological evaluation of novel podophyllotoxin derivatives bearing 4β-disulfide/trisulfide bond as cytotoxic agents

A novel series of C-4β-disulfide/trisulfide-containing podophyllotoxin derivatives were designed, synthesized, and biologically evaluated for their cytotoxic activities against human cancer cell lines, including KB (Mouth Epidermal Carcinoma Cells) and KB/VCR (Vincristine-resistant Mouth Epidermal Carcinoma Cells). Most of these compounds exhibited promising moderate to good cytotoxic activities. In particular, some of them displayed even superior activities to that of etoposide, especially for KB/VCR cell lines, indicating that introduction of the disulfide/trisulfide moiety would be beneficial for overcoming the multi-drug resistant limitation of etoposide. Moreover, the metabolic evaluation of the most promising compound was further performed to reveal that disulfide bond can be stable in human plasma over 8 hours, indicating good potential of these compounds for in vivo anti-cancer activities.

Synergistine derivatives and their preparation

The invention provides new synergistine derivatives of the formula: STR1 in which Y=H or N(CH3)2 and R represents: (a) H or OH, (b) a radical of the formula NR1 R2, in which R1 and R2 =H, phenyl or pyridyl (optionally substituted by dialkylamino (1 to 4 C), alkyl (1 to 10 C) [optionally substituted by OH, SH, COOH, anilino, or alkylamino or dialkylamino of which at least one of the alkyl parts is substituted by OH, SH, COOH or anilino 9 , alkenyl (3 or 4 C) or alkynyl (3 or 4 C), or alternatively R1 and R2 together form a heterocycle optionally containing another heteroatom such as O, S or N (optionally substituted by alkyl), or (c) a halogen atom, a trimethylsilyloxy or dialkylphosphoryloxy radical or a radical --OSO2 R3 or --OCOR4, R3 being alkyl, trifluoromethyl, trichloromethyl or optionally substituted phenyl and R4 being defined in the same way as R3 or being an acylalkyl, alkoxycarbonylalkyl or alkoxy radical, and also their salts and their preparation. These products are useful as intermediates in the synthesis of anti-bacterial synergistine derivatives.